Vascular effects of estrogen and progestins and risk of coronary artery disease: Importance of timing of estrogen treatment

Angiology

Volumn 60, Issue 3, 2009, Pages 308-317

  Gungor, Funda ^a,c   Kalelioglu, Ibrahim ^b   Turfanda, Abdullah ^b  

^a State Hospital of Dursunbey   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Department of Obstetrics and Gynecology ^*  (Turkey)

Author keywords

Coronary artery disease; Estrogen; Hormone replacement therapy; Menopause; Progesterone

Indexed keywords

CYPROTERONE ACETATE PLUS ESTRADIOL VALERATE; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NITRIC OXIDE; PROSTACYCLIN;

ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE COURSE; DNA POLYMORPHISM; DRUG MECHANISM; GENE CONTROL; GENETIC TRANSCRIPTION; HEART PROTECTION; HUMAN; MENOPAUSAL SYNDROME; NONHUMAN; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; VASCULARIZATION; AGE; BLOOD; CORONARY BLOOD VESSEL; DRUG ADMINISTRATION; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; METHODOLOGY; PATHOLOGY; POSTMENOPAUSE; VASCULAR ENDOTHELIUM;

AGE FACTORS; CORONARY ARTERY DISEASE; CORONARY VESSELS; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; NITRIC OXIDE; POSTMENOPAUSE;

EID: 67849090615     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319708318377     Document Type: Review

References (87)

1. Minirio AM, Heron MP, Murphy SL, Kochanek KD ; Centers for Disease Control and Prevention National Center for Health Statistics National Vital Statistics System. Deaths: final data for 2004. Natl Vital Stat Rep. 2007 ; 55: 1-119.
2. Dubey RK, Imthurn B., Barton M., Jackson EK Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res. 2005 ; 66: 295-306.
3. Stampfer MJ, Willett WC, Colditz GA, Rosner B., Speizer FE, Hennekens CH A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985 ; 313: 1044-1049.
4. Grodstein F., Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000 ; 133: 933-941.
5. Grady D., Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992 ; 117: 1016-1037.
6. Grady D., Herrington D., Bittner V., et al. Cardiovascular disease outcomes during 6.8 years of hormone replacement therapy. Heart Estrogen/Progestin Replacement Study Follow-up (HERS-II). JAMA. 2002 ; 288: 49-57. (Pubitemid 34705518)
7. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002 ; 288: 321-333.
8. Gebbie A. What's new in hormone replacement therapy. Medicine. 2007 ; 35: 529-532.
9. Mendelsohn ME Protective effects of estrogen on the cardiovascular system. Am J Cardiol. 2002 ; 89 (suppl): 12E - 18E.
10. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the million women study. Lancet. 2003 ; 362: 419-427.
11. Gilligan DM, Quyyumi AA, Cannon RO III. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 1994 ; 89: 2545-2551.
12. Imthurn B., Rosselli M., Jaeger AW, Keller PJ, Dubey RK Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J Clin Endocrinol Metab. 1997 ; 82: 388-394.
13. Collins P., Shay J., Jiang C., Moss J. Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation after acute estrogen withdrawal. Circulation. 1994 ; 90: 1964-1968.
14. Ylikorkala O., Cacciatore B., Paakkari I., Tikkanen MJ, Viinikka L., Toivonen J. The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane. Fertil Steril. 1998 ; 69: 883-888.
15. Kavser K., Rubanyi GM Potential cellular signaling mechanism mediating upregulation of endothelial nitric oxide production by estrogen. J Vasc Res. 1997 ; 34: 229-236.
16. Arnal JF, Clamens S., Pechet C., et al. Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production. Proc Natl Acad Sci U S A. 1996 ; 93: 4108-4113.
17. Russell KS, Haynes MP, Sinha D., Clerisme E., Bender JR Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci U S A. 2000 ; 97: 5930-5935.
18. Hisamoto K., Bender JR Vascular cell signaling by membrane estrogen receptors. Steroids. 2005 ; 70: 382-387.
19. Simoncini T., Rabkin E., Liao JK Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells. Arterioscler Thromb Vasc Biol. 2003 ; 23: 198-203.
20. Schulz E., Anter E., Zou MH, Keaney JF Jr. Estradiol mediated endothelial nitric oxide synthase association with heat shock protein 90 requires adenosine monophosphate-dependent protein kinase. Circulation. 2005 ; 111: 3473-3480.
21. Chester AH, Jiang C., Borland JA, Yacoub M., Collins P. Oestrogen relaxes human epicardial coronary arteries through non-endothelial dependent mechanisms. Coron Artery Dis. 1995 ; 6: 417-422.
22. Collins P., Rosano GM, Jiang C., Lindsay D., Sarrel PM, Poole-Wilson PA Cardiovascular protection by estrogen-a calcium antagonism effect ? Lancet. 1993 ; 341: 1264-1265.
23. Félétou M., Vanhoutte PM EDHF: new therapeutic targets ? Pharmacol Res. 2004 ; 49: 565-580.
24. Hermenegildo C., Oviedo PJ, Cano A. Cyclooxygenases regulation by estradiol on endothelium. Curr Pharm Des. 2006 ; 12: 205-215.
25. Simon A., Gariepy J., Chironi G., Megnien JL, Levenson J. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens. 2002 ; 20: 159-169.
26. Nakamura Y., Suzuki Y., Miki C., et al. Estrogen receptors in atherosclerotic human aorta: inhibition of human vascular smooth muscle cell proliferation by estrogens. Mol Cell Endocrinol. 2004 ; 219: 17-26.
27. Boyle EM, Lille ST, Allaire E., Clowes AW, Verrier ED Endothelial cell injury in cardiovascular surgery: atherosclerosis. Ann Thorac Surg. 1997 ; 63: 885-894.
28. Boyle EM, Verrier ED, Spiess BD Endothelial cell injury in cardiovascular surgery: the procoagulant response. Ann Thorac Surg. 1996 ; 62: 1549-1557.
29. Torry DS, Torry RJ Angiogenesis and the expression of vascular endothelial growth factor in endometrium and placenta. Am J Reprod Immunol. 1997 ; 37: 21-29.
30. Smith SK Angiogenesis, vascular endothelial growth factor and the endometrium. Hum Reprod Update. 1998 ; 4: 509-519.
31. Rubanyi GM, Johns A., Kauser K. Effects of estrogen on endothelial function and angiogenesis. Vascul Pharmacol. 2002 ; 38: 89-98.
32. Imanishi T., Kobayashi K., Hano T., Nishio I. Effect of estrogen on differentiation and senescence in endothelial progenitor cells derived from bone marrow in spontaneously hypertensive rats. Hypertens Res. 2005 ; 28: 763-772.
33. Imanishi T., Kobayashi K., Hano T., Nishio I. Estrogen reduces endothelial progentior cell senescence through augmentation of telomerase activity. J Hypertens. 2005 ; 23: 1699-1706.
34. Zhao X., Huang L., Yin Y., Fang Y., Zhao J., Chen J. Estrogen induces endothelial progenitor cells proliferation and migration by estrogen receptors and PI3Kdependent pathways. Microvasc Res. 2008 ; 75: 45-52.
35. Lacut K., Oger E., Le Gal G., et al. SARAH investigators. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost. 2003 ; 90: 124-131.
36. O'Brien KD, McDonald TO, Chait A., Allen MD, Alpers CE Neovascular expression of E-selectin, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation. 1996 ; 93: 672-682.
37. Shifren JL, Rifai N., Desindes S., McIlwain M., Doros G., Mazer N. A comparison of the short-term effects of oral conjugated equine estrogens vs transdermal estradiol on C-reactive protein, other serum markers of inflammation and other hepatic proteins in naturally menopausal women [published online ahead of print February 26, 2008]. J Clin Endocrin Metab. doi:10.1210/jc.2007- 2193.
38. Zanger D., Yang BK, Ardans J., et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol. 2000 ; 36: 1797-1802.
39. Störk S., von Schacky C., Angerer P. The effect of 17β-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized controlled trial. Atherosclerosis. 2002 ; 165: 301-307.
40. Cushman M., Legault C., Barrett-Connor E., et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestins Interventions (PEPI) study. Circulation. 1999 ; 100: 717-722.
41. Störk S., Baumann K., von Schacky C., Angerer P. The effect of 17β-estradiol on MCP-1 serum levels in postmenopausal women. Cardiovasc Res. 2002 ; 53: 642-649.
42. Clarkson TB Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause. 2007 ; 14: 373-384.
43. Zegura B., Guzic-Salobir B., Sebestjen M., Keber I. The effects of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause. 2006 ; 13: 643-650.
44. Rifici VA, Khachadurian AK The inhibition of low-density lipoprotein oxidation by 17-beta estradiol. Metabolism. 1992 ; 41: 1110-1114.
45. Vihma V., Vehkavaara S., Yki-Järvinen H., Hohtari H., Tikkanen MJ Differential effects of oral and transdermal estradiol treatment on circulating estradiol fatty acid ester concentrations in postmenopausal women. J Clin Endocrinol Metab. 2003 ; 88: 588-593.
46. Lam KK, Lee YM, Hsiao G., Chen SY, Yen MH Estrogen therapy replenishes vascular tetrahydrobiopterin and reduces oxidative stress in ovariectomized rats. Menopause. 2006 ; 13: 294-302.
47. Karim R., Mack WJ, Lobo R., et al. Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: estrogen in the prevention of atherosclerosis trial. Menopause. 2005 ; 12: 366-373. (Pubitemid 41098649)
48. Salpeter SR, Walsh JM, Ormiston TM, Greyber E., Buckley NS, Salpeter EE Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006 ; 8: 538-554.
49. Kernohan AFB, Sattar N., Hilditch T., et al. Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes. Clin Endocrinol. 2007 ; 66: 27-34.
50. Zhu BT, Conney AH Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis. 1998 ; 19: 1-37.
51. Dubey RK, Tofovic SP, Jackson EK Cardiovascular pharmacology of estradiol metabolites. J Pharmacol Exp Ther. 2004 ; 308: 403-409.
52. Cushman M., Kuller LH, Prentice R., et al. Women's Health Initiative Investigators. Etrogen plus progestin and risk of venous thrombosis. JAMA. 2004 ; 292: 1573-1580.
53. Cananico M., Oger E., Plu-Bureau G., et al. Estrogen and Thromboembolism Risk Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007 ; 115: 840-845.
54. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-β- estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis. 1990 ; 10: 1051-1057.
55. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1997 ; 17: 217-221.
56. Clarkson TB, Anthony MS, Wagner JD A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocrinol Metab. 2001 ; 86: 5396-5404.
57. Manson JE, Hsia J., Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003 ; 349: 523-534.
58. Hsia J., Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease. The women's health initiative. Arch Intern Med. 2006 ; 166: 357-365. (Pubitemid 43244325)
59. Grodstein F., Manson JE, Stampfer MJ Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women's Health. 2006 ; 15: 35-44. (Pubitemid 43192860)
60. Gompel A., Barlow D., Rozenberg S., Skouby SO Updating the EMAS 2004/2005 clinical recommendations on postmenopausal therapy following the recent publications: WHI and nurses' health study. Maturitas. 2006 ; 55: 1-4.
61. Salpeter SR, Walsh JM, Greyber E., Salpeter EE Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med. 2006 ; 21: 363-366.
62. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001 ; 135: 939-953.
63. Losordo DW, Kearney M., Kim EA, Jekanowski J., Isner JM Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of pre-menopausal women. Circulation. 1994 ; 89: 1501-1510.
64. Post WS, Goldschmidt-Clermont PJ, Wilhide CC, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res. 1999 ; 43: 985-991.
65. Shearman AM, Cupples LA, Demissie S., et al. Association between estrogen receptor-α gene variation and cardiovascular disease. JAMA. 2003 ; 290: 2263-2270.
66. Ogawa S., Emi M., Shiraki M., Hosoi T., Ouchi Y., Inoue S. Association of estrogen receptor-beta (ESR2) gene polymorphism with blood pressure. J Hum Genet. 2000 ; 45: 327-330.
67. Matsubara Y., Murata M., Kawano K., et al. Genotype distribution of estrogen receptor polymorphisms in men and postmenopausal women from healthy and coronary populations and its relation to serum lipid levels. Arterioscler Thromb Vasc Biol. 1997 ; 17: 3006-3012.
68. Karas RH Current controversies regarding the cardiovascular effects of hormone therapy. Clin Obstet Gynecol. 2004 ; 47: 489-499.
69. Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 2001 ; 103: 276-283.
70. Fukumoto Y., Libby P., Rabkin E., et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation. 2001 ; 103: 993-999.
71. Cribby M., Nordin-Fredriksson G., Shah PK, Yano J., Zhu J., Nilsson J. Provastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001 ; 103: 926-933.
72. Hild-Petito S., Stouffer RL, Brenner RM Immunocytochemical localization of estradiol and progesterone receptors in the monkey ovary throughout the menstrual cycle. Endocrinology. 1988 ; 123: 2896-2905.
73. Selles J., Polini N., Alvarez C., Massheimer V. Nongenomic action of progesterone in rat aorta: role of nitric oxide and prostaglandins. Cell Signal. 2002 ; 14: 431-436.
74. Hermenegildo C., Oviedo PJ, Garcia-Martinez MC, Garcia-Perez MA, Tarin JJ, Cano A. Progestogens stimulate prostacyclin production by human endothelial cells. Hum Reprod. 2005 ; 20: 1554-1561.
75. Rosano GMC, Leonardo F., Sarrel PM, Beale C., De Luca F., Collins P. Cyclical variation in paroxysmal supraventricular tachycardia in women. Lancet. 1996 ; 347: 786-788.
76. Pedersen NG, Pedersen SH, Dalsgaard T., Lund CO, Nilas L., Ottesen B. Progestins used in hormonal replacement therapy display different effects in coronary arteries from New Zealand white rabbits. Maturitas. 2004 ; 49: 304-314.
77. Clarkson TB, Appt SE MPA and postmenopausal coronary artery atherosclerosis revisited. Steroids. 2003 ; 68: 941-951.
78. Simoncini T., Mannella P., Fornari L., et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology. 2004 ; 145: 5745-5756.
79. Levine RL, Chen SJ, Durand J., Chen YF, Oparil S. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation. 1996 ; 94: 2221-2227. (Pubitemid 26360517)
80. Herkert O., Kuhl H., Sandow J., Busse R., Schini-Kerth VB Sex steroids used hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression. Role of the glucocorticoid receptor. Circulation. 2001 ; 104: 826-831.
81. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2004 ; 47: 277-283.
82. Sitruk-Ware R. Progestins and cardiovascular risk markers. Steroids. 2000 ; 65: 651-658.
83. The Writing Group for the PEPI Trial. Effects of androgen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin (PEPI) trial. JAMA. 1995 ; 273: 199-208.
84. Crook D., Cust MP, Gangar KF, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol. 1992 ; 166: 950-955.
85. Simoncini T., Mannella P., Fornari L., Caruso A., Varone G., Genazzani AR In vitro effects of progesterone and progestins on vascular cells. Steroids. 2003 ; 68: 831-836.
86. Winkler UH Effects of progestins on cardiovascular diseases: the haemostatic system. Hum Reprod Update. 1999 ; 5: 200-204.
87. Barrett-Connor E., Slone S., Greendale G., et al. The postmenopausal estrogen/progestin interventions study; primary outcomes in adherent women. Maturitas. 1997 ; 27: 261-274.